WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation
Highlights • HCC cells with p53 expression displayed enhanced sensitivity. • p53 depletion abolished the synergistic cytotoxicity. • WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation. • usp9x downregulation abolished the synergistic cytotoxic effects of WP1130. • Tenovin-1 decreas...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2015-06, Vol.361 (2), p.218-225 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 225 |
|---|---|
| container_issue | 2 |
| container_start_page | 218 |
| container_title | Cancer letters |
| container_volume | 361 |
| creator | Liu, Hao Chen, Wei Liang, Chao Chen, Bryan Wei Zhi, Xiao Zhang, Shufeng Zheng, Xiaoxiao Bai, Xueli Liang, Tingbo |
| description | Highlights • HCC cells with p53 expression displayed enhanced sensitivity. • p53 depletion abolished the synergistic cytotoxicity. • WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation. • usp9x downregulation abolished the synergistic cytotoxic effects of WP1130. • Tenovin-1 decreased the doxorubicin cytotoxicity in the presence of WP1130. |
| doi_str_mv | 10.1016/j.canlet.2015.03.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1709177203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383515001688</els_id><sourcerecordid>1709177203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c614t-4d1877441e0faa9b2295322b3e57a4c9aa3c069535bb76be55c73871484b41153</originalsourceid><addsrcrecordid>eNqFkk-LFDEQxYMo7uzqNxBp8OKl21T-dLovgiy6CgsKKh5DOl2zk7EnaZP0svPtTTOrwl48BYrfq7yqV4S8ANoAhfbNvrHGT5gbRkE2lDeUwiOygU6xWvUdfUw2lFNR847LM3Ke0p5SKoWST8kZk0r0grENiT--AHBaOW8jmoSpGsNdiMvgrPNVQp9cdrcuHwtR7XA2OVicpmUysbImFigcTLWWUpV3MSw3u2pJc39XjzijH9Hnapa8GvEmmtFkF_wz8mRrpoTP798L8v3D-2-XH-vrz1efLt9d17YFkWsxllGUEIB0a0w_MNZLztjAUSojbG8Mt7QtNTkMqh1QSqt4p0B0YhAAkl-Q16e-cwy_FkxZH1xanRqPYUkaFO1BKUZ5QV89QPdhib6409AWDx0IDoUSJ8rGkFLErZ6jO5h41ED1mone61Mmes1EU65LJkX28r75Mhxw_Cv6E0IB3p4ALNu4dRh1sg69xdFFtFmPwf3vh4cN7OS8s2b6iUdM_2bRiWmqv653sZ4FyKJuu47_BuCAs0E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674481431</pqid></control><display><type>article</type><title>WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Liu, Hao ; Chen, Wei ; Liang, Chao ; Chen, Bryan Wei ; Zhi, Xiao ; Zhang, Shufeng ; Zheng, Xiaoxiao ; Bai, Xueli ; Liang, Tingbo</creator><creatorcontrib>Liu, Hao ; Chen, Wei ; Liang, Chao ; Chen, Bryan Wei ; Zhi, Xiao ; Zhang, Shufeng ; Zheng, Xiaoxiao ; Bai, Xueli ; Liang, Tingbo</creatorcontrib><description>Highlights • HCC cells with p53 expression displayed enhanced sensitivity. • p53 depletion abolished the synergistic cytotoxicity. • WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation. • usp9x downregulation abolished the synergistic cytotoxic effects of WP1130. • Tenovin-1 decreased the doxorubicin cytotoxicity in the presence of WP1130.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2015.03.001</identifier><identifier>PMID: 25749422</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Cancer therapies ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - pathology ; Cell growth ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Cyanoacrylates ; Cytotoxicity ; DNA repair ; Doxorubicin - administration & dosage ; Doxorubicin - pharmacology ; Drug resistance ; Drug Resistance, Neoplasm ; Drug Synergism ; Enzymes ; Hematology, Oncology and Palliative Medicine ; Hep G2 Cells ; Hepatocellular carcinoma ; Humans ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - metabolism ; Liver Neoplasms - pathology ; Mortality ; Nitriles - administration & dosage ; Nitriles - pharmacology ; p53 ; Proteins ; Pyridines - administration & dosage ; Pyridines - pharmacology ; Rodents ; Signal Transduction ; Transfection ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Ubiquitin Thiolesterase - genetics ; Ubiquitin Thiolesterase - metabolism ; usp9x ; WP1130</subject><ispartof>Cancer letters, 2015-06, Vol.361 (2), p.218-225</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 1, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c614t-4d1877441e0faa9b2295322b3e57a4c9aa3c069535bb76be55c73871484b41153</citedby><cites>FETCH-LOGICAL-c614t-4d1877441e0faa9b2295322b3e57a4c9aa3c069535bb76be55c73871484b41153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2015.03.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25749422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Hao</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Liang, Chao</creatorcontrib><creatorcontrib>Chen, Bryan Wei</creatorcontrib><creatorcontrib>Zhi, Xiao</creatorcontrib><creatorcontrib>Zhang, Shufeng</creatorcontrib><creatorcontrib>Zheng, Xiaoxiao</creatorcontrib><creatorcontrib>Bai, Xueli</creatorcontrib><creatorcontrib>Liang, Tingbo</creatorcontrib><title>WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • HCC cells with p53 expression displayed enhanced sensitivity. • p53 depletion abolished the synergistic cytotoxicity. • WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation. • usp9x downregulation abolished the synergistic cytotoxic effects of WP1130. • Tenovin-1 decreased the doxorubicin cytotoxicity in the presence of WP1130.</description><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cyanoacrylates</subject><subject>Cytotoxicity</subject><subject>DNA repair</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Synergism</subject><subject>Enzymes</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hep G2 Cells</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Mortality</subject><subject>Nitriles - administration & dosage</subject><subject>Nitriles - pharmacology</subject><subject>p53</subject><subject>Proteins</subject><subject>Pyridines - administration & dosage</subject><subject>Pyridines - pharmacology</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>Transfection</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Ubiquitin Thiolesterase - genetics</subject><subject>Ubiquitin Thiolesterase - metabolism</subject><subject>usp9x</subject><subject>WP1130</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk-LFDEQxYMo7uzqNxBp8OKl21T-dLovgiy6CgsKKh5DOl2zk7EnaZP0svPtTTOrwl48BYrfq7yqV4S8ANoAhfbNvrHGT5gbRkE2lDeUwiOygU6xWvUdfUw2lFNR847LM3Ke0p5SKoWST8kZk0r0grENiT--AHBaOW8jmoSpGsNdiMvgrPNVQp9cdrcuHwtR7XA2OVicpmUysbImFigcTLWWUpV3MSw3u2pJc39XjzijH9Hnapa8GvEmmtFkF_wz8mRrpoTP798L8v3D-2-XH-vrz1efLt9d17YFkWsxllGUEIB0a0w_MNZLztjAUSojbG8Mt7QtNTkMqh1QSqt4p0B0YhAAkl-Q16e-cwy_FkxZH1xanRqPYUkaFO1BKUZ5QV89QPdhib6409AWDx0IDoUSJ8rGkFLErZ6jO5h41ED1mone61Mmes1EU65LJkX28r75Mhxw_Cv6E0IB3p4ALNu4dRh1sg69xdFFtFmPwf3vh4cN7OS8s2b6iUdM_2bRiWmqv653sZ4FyKJuu47_BuCAs0E</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Liu, Hao</creator><creator>Chen, Wei</creator><creator>Liang, Chao</creator><creator>Chen, Bryan Wei</creator><creator>Zhi, Xiao</creator><creator>Zhang, Shufeng</creator><creator>Zheng, Xiaoxiao</creator><creator>Bai, Xueli</creator><creator>Liang, Tingbo</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20150601</creationdate><title>WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation</title><author>Liu, Hao ; Chen, Wei ; Liang, Chao ; Chen, Bryan Wei ; Zhi, Xiao ; Zhang, Shufeng ; Zheng, Xiaoxiao ; Bai, Xueli ; Liang, Tingbo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c614t-4d1877441e0faa9b2295322b3e57a4c9aa3c069535bb76be55c73871484b41153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cyanoacrylates</topic><topic>Cytotoxicity</topic><topic>DNA repair</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Synergism</topic><topic>Enzymes</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hep G2 Cells</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Mortality</topic><topic>Nitriles - administration & dosage</topic><topic>Nitriles - pharmacology</topic><topic>p53</topic><topic>Proteins</topic><topic>Pyridines - administration & dosage</topic><topic>Pyridines - pharmacology</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>Transfection</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Ubiquitin Thiolesterase - genetics</topic><topic>Ubiquitin Thiolesterase - metabolism</topic><topic>usp9x</topic><topic>WP1130</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Hao</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Liang, Chao</creatorcontrib><creatorcontrib>Chen, Bryan Wei</creatorcontrib><creatorcontrib>Zhi, Xiao</creatorcontrib><creatorcontrib>Zhang, Shufeng</creatorcontrib><creatorcontrib>Zheng, Xiaoxiao</creatorcontrib><creatorcontrib>Bai, Xueli</creatorcontrib><creatorcontrib>Liang, Tingbo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Hao</au><au>Chen, Wei</au><au>Liang, Chao</au><au>Chen, Bryan Wei</au><au>Zhi, Xiao</au><au>Zhang, Shufeng</au><au>Zheng, Xiaoxiao</au><au>Bai, Xueli</au><au>Liang, Tingbo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>361</volume><issue>2</issue><spage>218</spage><epage>225</epage><pages>218-225</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • HCC cells with p53 expression displayed enhanced sensitivity. • p53 depletion abolished the synergistic cytotoxicity. • WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation. • usp9x downregulation abolished the synergistic cytotoxic effects of WP1130. • Tenovin-1 decreased the doxorubicin cytotoxicity in the presence of WP1130.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>25749422</pmid><doi>10.1016/j.canlet.2015.03.001</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2015-06, Vol.361 (2), p.218-225 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1709177203 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis Apoptosis - drug effects Cancer therapies Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cell growth Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Cyanoacrylates Cytotoxicity DNA repair Doxorubicin - administration & dosage Doxorubicin - pharmacology Drug resistance Drug Resistance, Neoplasm Drug Synergism Enzymes Hematology, Oncology and Palliative Medicine Hep G2 Cells Hepatocellular carcinoma Humans Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - metabolism Liver Neoplasms - pathology Mortality Nitriles - administration & dosage Nitriles - pharmacology p53 Proteins Pyridines - administration & dosage Pyridines - pharmacology Rodents Signal Transduction Transfection Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Ubiquitin Thiolesterase - genetics Ubiquitin Thiolesterase - metabolism usp9x WP1130 |
| title | WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WP1130%20increases%20doxorubicin%20sensitivity%20in%20hepatocellular%20carcinoma%20cells%20through%20usp9x-dependent%20p53%20degradation&rft.jtitle=Cancer%20letters&rft.au=Liu,%20Hao&rft.date=2015-06-01&rft.volume=361&rft.issue=2&rft.spage=218&rft.epage=225&rft.pages=218-225&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2015.03.001&rft_dat=%3Cproquest_cross%3E1709177203%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1674481431&rft_id=info:pmid/25749422&rft_els_id=1_s2_0_S0304383515001688&rfr_iscdi=true |